Journal Article Research Support, N.I.H., Intramural Ppublish 21 citations
PubMed: 35788185 DOI: 10.1038/s41577-022-00744-x
Considering innate immune responses in SARS-CoV-2 infection and COVID-19.
Nat Rev Immunol 22(8):465-470
Authors: Michael S Diamond, John D Lambris, Jenny P Ting, John S Tsang
Affiliations
- Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Departments of Genetics, Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Center for Translational Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
- NIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.
- Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA.
Abstract
During the COVID-19 pandemic, much of the media focus has been on adaptive immunity, particularly antibody levels and memory T cells. However, immunologists have been striving to decipher how SARS-CoV-2 infection impacts our first line of defence, namely the innate immune system. In early 2022, Program staff from the NIAID at the NIH organized a workshop focusing on the innate immune response to SARS-CoV-2 infection and during COVID-19, which was chaired by Ralph Baric, Jenny Ting and John Lambris. Following the meeting, Nature Reviews Immunology invited some of the organizers and speakers to share their thoughts on the key discussion points.
MeSH
Sars-Cov-2, Covid-19, Immunity, Immunity, Innate, Severe Acute Respiratory Syndrome-Related Coronavirus, Infections
Cited by
- SARS-CoV-2 epitopes inform future vaccination strategies. Front Immunol, 2022
- Metallic nanoplatforms for COVID-19 diagnostics: versatile applications in the pandemic and post-pandemic era. J Nanobiotechnology, 2023
- Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. J Virol, 2025
- Editorial: The impact of COVID-19 on immune system-related complications in surgical patients. Front Surg, 2023
- Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. bioRxiv, 2024
- Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity. Virol J, 2022
- Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1. Sci Rep, 2023
- Macrophage phagocytosis of SARS-CoV-2-infected cells mediates potent plasmacytoid dendritic cell activation. Cell Mol Immunol, 2023
- Exacerbation of Behcet's Disease and Pyoderma Gangrenosum Following COVID-19 Infection: A Case Report. Cureus, 2023